Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

60.45 +1.12 (+1.88%)
Streaming Delayed Price Updated: 12:41 PM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
News headline image
Sell in May and Go Away—Starting With These 3 Stocks ↗
Oxford Club's Marc Lichtenfeld identifies three stocks worth selling in May—DexCom, Colgate-Palmolive, and Oracle—and breaks down the risks behind each call. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
2 Mid-Cap Stocks with Impressive Fundamentals and 1 We Question
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
News headline image
3 Quality Compounders Worth Your Attention
Quality compounders are flywheels. Said differently, they’re businesses that generate heaps of profits and consistently reinvest them to produce even more pr... 
Via StockStory
News headline image
5 Insightful Analyst Questions From DexCom’s Q1 Earnings Call
DexCom’s first quarter saw revenue growth driven by new product launches and increased adoption, particularly among people with type 2 diabetes who are not o... 
Via StockStory
Topics Earnings Economy
These S&P500 stocks have an unusual volume in today's session ↗
Via Chartmill
DexCom Inc (NASDAQ:DXCM): A GARP Stock with Affordable Growth and Strong Fundamentals ↗
Via Chartmill
News headline image
3 Reasons Analysts Love DexCom ↗
Via MarketBeat
Friday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
News headline image
DXCM Q1 Deep Dive: U.S. Growth Moderates as Product Momentum and Coverage Expansion Drive Strategy
Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 15% year on year to $1.19 bil... 
Via StockStory
News headline image
2 Nasdaq 100 Stocks with Solid Fundamentals and 1 We Find Risky
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win... 
Via StockStory
DexCom (NASDAQ:DXCM) Beats Q1 Earnings Forecasts, But Guidance and Revenue Miss Fuel After-Hours Drop ↗
Via Chartmill
DEXCOM INC (NASDAQ:DXCM) Shows Strong Fundamentals and a Promising Technical Breakout Setup ↗
Via Chartmill
News headline image
DexCom (DXCM) Q1 2026 Earnings Transcript ↗
DexCom (DXCM) Q1 2026 Earnings Transcript 
Via The Motley Fool
Top S&P500 movers in Thursday's after hours session ↗
Via Chartmill
News headline image
DexCom (NASDAQ:DXCM) Exceeds Q1 CY2026 Expectations But Stock Drops
Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 15% year on year to $1.19 b... 
Via StockStory
News headline image
2026 Market Cap Madness Championship: Loren v. Emily ↗
It’s time to crown a winner: defending champion Emily Flippen faces off against Cinderella challenger Loren Horst in the Market Cap Madness World Championship. 
Via The Motley Fool
News headline image
DexCom (DXCM) Q1 Earnings: What To Expect
Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings this Thursday after market close. Here’s what investors should know. DexCom beat analy... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock to Target This Week and 2 Facing Challenges
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins ↗
Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines. 
Via The Motley Fool
News headline image
Better Medical Device Stock Right Now: Abbott Laboratories vs. Dexcom ↗
They offer investors very different value propositions. 
Via The Motley Fool
News headline image
2 Healthcare Stocks That Could Outperform the Market Over the Next Decade ↗
Both have helped transform their respective industries. 
Via The Motley Fool
News headline image
3 Reasons Investors Love DexCom (DXCM)
Over the last six months, DexCom’s shares have sunk to $62.07, producing a disappointing 6.4% loss - a stark contrast to the S&P 500’s 5.1% gain. This may ha... 
Via StockStory
Topics Stocks
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session. 
Via Chartmill
News headline image
Q4 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks
Let’s dig into the relative performance of DexCom (NASDAQ:DXCM) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. Patient ... 
Via StockStory
Topics Artificial Intelligence
News headline image
DexCom Inc (NASDAQ:DXCM) Fits the Affordable Growth Investment Strategy ↗
DexCom (DXCM) exemplifies GARP investing, offering strong growth in glucose monitoring at a price reasonable relative to its industry and supported by robust profitability. 
Via Chartmill
News headline image
DexCom (DXCM) Q2 2025 Earnings Call Transcript ↗
DexCom (DXCM) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
DexCom (DXCM) Q3 2025 Earnings Call Transcript ↗
DexCom (DXCM) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring
Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require... 
Via MarketMinute
Topics Economy
News headline image
The Medtronic Transformation: A Deep Dive into the Future of a MedTech Titan
As of April 1, 2026, the global medical technology landscape is undergoing a profound shift, and at the center of this evolution is Medtronic plc (NYSE: MDT). Long regarded as the "sleeping giant" of... 
Via Finterra
Topics Artificial Intelligence Economy Initial Public Offering
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.